A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Obinutuzumab in Patients With ISN/RPS 2003 Class III or IV Lupus Nephritis
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 22 Mar 2018
At a glance
- Drugs Obinutuzumab (Primary) ; Mycophenolate mofetil
- Indications Lupus nephritis
- Focus Therapeutic Use
- Acronyms NOBILITY
- Sponsors Roche
- 31 Aug 2018 Biomarkers information updated
- 19 Mar 2018 Status changed from recruiting to active, no longer recruiting.
- 12 Feb 2018 Planned End Date changed from 27 Dec 2019 to 25 Dec 2019.